Clinical Trials

MainTitle

Preventing Bone Loss Among Chinese Patients With HIV on ART

This study is currently recruiting participants. (see Contacts and Locations)

Verified March 2019 by LI Taisheng, Peking Union Medical College Hospital

Sponsor
Peking Union Medical College Hospital

Collaborator
Beijing YouAn Hospital
Beijing Ditan Hospital
Guangxi Autonomous Region Longtan Hospital
Fuzhou Infectious Diseases Hospital
Shenzhen Third People's Hospital
Yale University

Information provided by (Responsible Party)
LI Taisheng, Peking Union Medical College Hospital

ClinicalTrials.gov Identifier
NCT03598556

First received: July 15, 2018
Last updated: March 25, 2019
Last Verified: March 2019
History of Changes
Purpose

Purpose

The major goal of this study will be to conduct a randomized, double-blind, placebo-controlled, clinical trial of intermittent high-dose vitamin D3 supplementation (180,000IU) given at the point of care (every 3 months) after initiation of ART with tenofovir/ lamivudine/ efavirenz to compare its ability to mitigate reductions in bone mineral density over 12 months compared to placebo.

Condition Intervention
HIV/AIDS
Osteoporosis
Bone Loss

Dietary Supplement : Vitamin D3
Other : Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Strategies for the Prevention of Bone Loss Among Patients With HIV on Antiretroviral Therapy in China

Further study details as provided by LI Taisheng, Peking Union Medical College Hospital:

Primary Outcome Measures

  • Change in Bone Mineral Density (BMD) [ Time Frame: Baseline to week 48 ]
    In the three sites in Beijing (N=400), compare percent change in BMD at the lumbar spine and total hip, as measured by dual-energy x-ray absorptiometry (DXA) at week 48.
Secondary Outcome Measures:
  • Immediate vs. Delayed Vitamin D3 Supplementation [ Time Frame: Weeks 48 to 96 ]
    In the three sites in Beijing (N=400), from 48 to 96 weeks, switch the placebo arm to vitamin D3 supplementation to compare percent change in BMD at 96 weeks between patients who initiated vitamin D3 supplementation at the start of ART versus those who initiated vitamin D3 after 1 year of ART.
  • Change in Quantitative Ultrasound (QUS) Measures [ Time Frame: Baseline to 96 weeks ]
    In all six study sites (N=600), evaluate percent change in SOS and BUA over 48 weeks in the vitamin D treatment group compared with placebo, as measured by QUS. Further, evaluate the ability of QUS to independently identify the same group of patients at greatest risk for severe bone loss, as compared with risk stratification using DXA.
  • Change in Biochemical Markers [ Time Frame: Baseline to 96 weeks ]
    To measure the effect of the proposed intervention on markers of vitamin D and bone metabolism, inflammation and HIV disease status.

Estimated Enrollment: 600
Study Start Date: June 1, 2018
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: Vitamin D3 Supplementation Arm
This arm will receive 180,000IU vitamin D3 every 3 months from baseline through week 96.
Dietary Supplement: Vitamin D3

180,000IU Vitamin D3 oral emulsion

Placebo Comparator: Placebo Arm
This arm will receive placebo every 3 months from baseline through week 48, followed by 180,000IU vitamin D3 every 3 months from week 48 through week 96.
Other: Placebo

Placebo

Detailed Description:

Studies among adult and pediatric populations have suggested vitamin D supplementation may be efficacious for mitigating the bone loss seen with tenofovir-based antiretroviral therapy (ART). Because patients with HIV face significant pill burden, competing priorities and health care associated costs, we seek to explore a pragmatic approach to prevention. The investigators propose a randomized controlled, double-blind, placebo intervention trial to assess the efficacy, tolerability, and safety of an intermittent high-dose vitamin D3 supplementation regimen given quarterly at the point of care for adult patients receiving free ART through the China National Free AIDS Treatment Program. The period of supplementation will be limited to the first 48 weeks after treatment initiation when ART-associated bone loss is most pronounced. This will be followed by supplementation of all participants with vitamin D3 from 48 to 96 weeks to compare the impact of early vitamin D3 supplementation (at ART initiation) versus late vitamin D3 supplementation (at 48 weeks) on change in BMD.
Furthermore, despite the rapid rise in access to ART in China, infrastructure to diagnose and manage osteoporosis is not always easily accessible for patients with HIV in China due to limited availability of dual-energy x-ray absorptiometry (DXA), the gold standard for BMD measurement. Therefore, the current proposal also seeks to bridge this gap by exploring the potential applications of quantitative ultrasound (QUS), a portable and low-cost method of assessing BMD that has been demonstrated to reliably predict fracture, in HIV care settings.
A total of 400 treatment-naïve Chinese adults diagnosed with HIV from 3 study sites in Beijing will be enrolled and followed with serial DXA exams to evaluate the primary aim. These 400 patients plus another 200 participants from 3 additional study sites from Fuzhou, Shenzhen, and Guangxi province, will be evaluated with serial QUS ultrasound examinations for the secondary aims. Serum and urine samples will be collected and stored at pre-specified time points.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years to 65 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria:

  • Provision of signed and dated informed consent form
  • Willingness and availability to engage in study activities for the duration of the study
  • Documented HIV-1 infection (confirmed by Western blot)
  • ART naïve at the time of enrollment
  • Eligible to initiate ART (TDF/3TC/EFV) within 1 month
  • Ability to take oral medication and be willing to adhere to the mediation regimen
  • For females of reproductive potential: use of highly effective contraception


Exclusion Criteria:
  • Pregnancy or breastfeeding
  • AIDS-defining illness within 2 weeks of entry
  • Liver disease (transaminase and alkaline phosphatase levels more than three times the upper limit of the normal range (ULN), bilirubin level more than 2.5 times the ULN)
  • Chronic kidney disease (serum creatinine level more than 1.5 times the ULN)
  • Patients with a history of injection drug usage
  • Known history of osteoporosis, osteoporotic fracture, or other metabolic/inherited bone disorder
  • History of treatment with prescription therapies for osteoporosis (for example: bisphosphonates, denosumab, teriparatide, selective estrogen receptor modifying agents, active forms of vitamin D).
  • Unwillingness to discontinue previous vitamin D supplementation, if any, at time of enrollment
  • Rheumatoid arthritis
  • Malabsorption or inflammatory bowel disease
  • Hyperparathyroidism, hypercalcemia, or hypocalcemia
  • History of kidney stones
  • Poorly controlled thyroid disease
  • History of neuromuscular disorder/movement disorder, stroke or seizures
  • History of significant neurocognitive disorders (including mental health conditions or dementia)
  • Glucocorticoids, estrogen, testosterone, or anticonvulsant use within the past six
months

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03598556

Contacts

Contact:   Evelyn Hsieh, MD, PhD +86-10-6529-5086 evelyn.hsieh@yale.edu
Contact:   Wei Cao, MD +86-10-6529-5086 wcao_pumch@163.com

Locations

China
Beijing Ditan Hospital Recruiting
Beijing, Beijing, China
Contact: Hongxin Zhao, MD
Beijing Youan Hospital Recruiting
Beijing, Beijing, China
Contact: Wen Wang, MD
Peking Union Medical College Hospital Recruiting
Beijing, Beijing, China
Contact: Evelyn Hsieh, MD, PhD    +86-10-6529-5086    evelyn.hsieh@yale.edu
Contact: Wei Cao, MD    +86-10-6529-5086    wcao_pumch@163.com
Fuzhou Infectious Diseases Hospital Recruiting
Fuzhou, Fujian, China
Contact: Hanhui Ye, MD
Shenzhen Third Hospital Recruiting
Shenzhen, Guangdong, China
Contact: Yun He, MD
Longtan Hospital Recruiting
Liuzhou, Guangxi Autonomous Region, China
Contact: Zhihao Meng, MD

Sponsors and Collaborators

Peking Union Medical College Hospital
Beijing YouAn Hospital
Beijing Ditan Hospital
Guangxi Autonomous Region Longtan Hospital
Fuzhou Infectious Diseases Hospital
Shenzhen Third People's Hospital
Yale University

Investigators

Principal Investigator: Taisheng Li, MD, PhD Peking Union Medical College Hospital
More Information

More Information


Responsible Party: LI Taisheng, Professor, Department of Infectious Diseases, Peking Union Medical College Hospital  
ClinicalTrials.gov Identifier: NCT03598556   History of Changes  
Other Study ID Numbers: CACT 1807  
Study First Received: July 15, 2018  
Last Updated: March 25, 2019  

Studies a U.S. FDA-regulated Drug Product: No  
Studies a U.S. FDA-regulated Device Product: No  

Keywords provided by LI Taisheng, Peking Union Medical College Hospital:

China
Anti-retroviral Therapy
Vitamin D
Tenofovir
Efavirenz
Lamivudine

Additional relevant MeSH terms:
Osteoporosis
Vitamin D
Cholecalciferol

ClinicalTrials.gov processed this data on May 24, 2020
This information is provided by ClinicalTrials.gov.